PL353785A1 - Method of treating or inhibiting neurophylic chemotaxis by administering the mek inhibitor - Google Patents

Method of treating or inhibiting neurophylic chemotaxis by administering the mek inhibitor

Info

Publication number
PL353785A1
PL353785A1 PL02353785A PL35378502A PL353785A1 PL 353785 A1 PL353785 A1 PL 353785A1 PL 02353785 A PL02353785 A PL 02353785A PL 35378502 A PL35378502 A PL 35378502A PL 353785 A1 PL353785 A1 PL 353785A1
Authority
PL
Poland
Prior art keywords
neurophylic
chemotaxis
administering
inhibiting
treating
Prior art date
Application number
PL02353785A
Other languages
English (en)
Inventor
Vijaykumar Mahalingappa Baragi
Madhav Narasimha Devalaraja
Joseph Edwin Low
Vaishalee Arvind Padgaonkar
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PL353785A1 publication Critical patent/PL353785A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02353785A 2001-05-09 2002-05-09 Method of treating or inhibiting neurophylic chemotaxis by administering the mek inhibitor PL353785A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28988101P 2001-05-09 2001-05-09

Publications (1)

Publication Number Publication Date
PL353785A1 true PL353785A1 (en) 2002-11-18

Family

ID=23113527

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02353785A PL353785A1 (en) 2001-05-09 2002-05-09 Method of treating or inhibiting neurophylic chemotaxis by administering the mek inhibitor

Country Status (12)

Country Link
US (1) US6972298B2 (enExample)
EP (1) EP1262176A1 (enExample)
JP (1) JP2002332247A (enExample)
KR (1) KR20020085852A (enExample)
CN (1) CN1383823A (enExample)
AU (1) AU3821502A (enExample)
CA (1) CA2385412A1 (enExample)
HU (1) HUP0201542A3 (enExample)
IL (1) IL149462A0 (enExample)
NZ (1) NZ518726A (enExample)
PL (1) PL353785A1 (enExample)
ZA (1) ZA200203668B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2005007616A1 (en) * 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
WO2005028426A1 (ja) * 2003-09-19 2005-03-31 Chugai Seiyaku Kabushiki Kaisha 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
BRPI0415710A (pt) * 2003-10-21 2006-12-19 Warner Lambert Co formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
PT2298768E (pt) 2004-06-11 2012-12-05 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
EP2049493B1 (en) * 2006-07-31 2012-03-21 Cadila Healthcare Limited Compounds suitable as modulators of hdl
ES2703723T3 (es) 2006-12-14 2019-03-12 Exelixis Inc Métodos para usar inhibidores de MEK
CL2008001373A1 (es) * 2007-05-11 2008-11-21 Bayer Schering Pharma Ag Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
EP2203411B1 (en) * 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2711558C (en) 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
ES2557316T3 (es) 2009-09-08 2016-01-25 F. Hoffmann-La Roche Ag Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
CA2790176A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
ES2575995T3 (es) 2010-08-05 2016-07-04 Case Western Reserve University Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
US20120095060A1 (en) * 2010-10-14 2012-04-19 Hardie William D Methods and compositions of mitogen-activated protein kinase (mapk) pathway inhibitors for treating pulmonary fibrosis
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
JP5997763B2 (ja) 2011-05-19 2016-09-28 フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ Ｃａｒｌｏｓ ＩＩＩ タンパク質キナーゼ阻害剤としての大環状化合物
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
HRP20180670T1 (hr) 2012-10-12 2018-07-13 Exelixis Inc. Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US20140120060A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
EP3043790B1 (en) * 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
MX2017000546A (es) 2014-07-15 2017-03-08 Genentech Inc Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
MX2021012639A (es) * 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
AU2018349376A1 (en) * 2017-10-09 2020-05-07 Ramot At Tel-Aviv University Ltd. Modulators of potassium ion and TRPV1 channels and uses thereof
US12011446B2 (en) * 2018-04-20 2024-06-18 Thomas Jefferson University Method of using MeK inhibitor to prevent radiation induced fibrosis
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2025043043A2 (en) * 2023-08-24 2025-02-27 Musc Foundation For Research Development Mek1 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
AU757046B2 (en) * 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
JP2002509536A (ja) * 1997-07-01 2002-03-26 ワーナー−ランバート・カンパニー ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase
AU1951499A (en) * 1998-01-06 1999-07-26 General Hospital Corporation, The Use of mek1 inhibitors as protective agents against damage due to ischemia
TR200101704T2 (tr) 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
HRP20010473A2 (en) 1998-12-22 2002-08-31 Warner Lambert Co Combination chemotherapy
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
DE69924641D1 (de) * 1999-01-07 2005-05-12 Warner Lambert Company Llc Mor Behandlung von asthma anhand von mek-inhibitoren
AU2201500A (en) * 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
KR20020012315A (ko) 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
DK2223922T3 (en) * 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
WO2002006213A2 (en) * 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1420778B1 (en) 2001-03-06 2006-11-22 Dorian Bevec Use of mek inhibitors for treating virus induced hemorrhagic shock or fever
EP1377312A4 (en) 2001-03-22 2004-10-06 Andel Inst Van ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS

Also Published As

Publication number Publication date
JP2002332247A (ja) 2002-11-22
HUP0201542A3 (en) 2003-10-28
ZA200203668B (en) 2002-12-20
CA2385412A1 (en) 2002-11-09
KR20020085852A (ko) 2002-11-16
CN1383823A (zh) 2002-12-11
NZ518726A (en) 2004-06-25
AU3821502A (en) 2002-11-14
US20030055095A1 (en) 2003-03-20
HUP0201542A2 (hu) 2003-01-28
IL149462A0 (en) 2002-11-10
US6972298B2 (en) 2005-12-06
EP1262176A1 (en) 2002-12-04
HU0201542D0 (enExample) 2002-07-29

Similar Documents

Publication Publication Date Title
ZA200203668B (en) Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor.
IL241920A0 (en) A method for treating multiple sclerosis
PL364995A1 (en) Method for the treatment or prevention of flavivirus
HUP0402629A3 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2003247624A8 (en) Method of treating the syndrome of lipodystrophy
IL233205B (en) Substances for the treatment or prevention of pre-eclampsia
PL373658A1 (en) Treatment of gastroparesis
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
MXPA02012907A (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
GB2389532C (en) The method of treating cancer
GB0112216D0 (en) Method of treatment
ZA200303274B (en) Method of treating shellfish.
EP1389129A4 (en) METHOD FOR TREATING RESPIRATORY DISEASES
GB0118892D0 (en) Method of treatment
IL161630A0 (en) Methods of treating endometreosis
GB0213198D0 (en) Method of treatment
TJ20010676A (en) Method treatment cirrosis of the liver
GB0207091D0 (en) Method of treatment
SI1307262T1 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
GB0126094D0 (en) Method of treatment
GB0111487D0 (en) Method of treatment
GB0116029D0 (en) Method of treatment
GB0125105D0 (en) Method of treatment
EP1583765A4 (en) COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES CHARACTERIZED BY THE PRESENCE OF METALLIC IONS
GB0230014D0 (en) Kinase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases and nucleotide sequences

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)